Innovo Therapeutics Email Format

Biotechnology ResearchCalifornia, United States2-10 Employees

Innovo Therapeutics is a biotechnology research company focused on discovering and developing the next generation of protein degraders to address areas of high unmet medical need. Its TriNovo platform enables targeted protein degradation, complemented by a proprietary phenotypic screening system to build and rapidly expand a high-quality, differentiated pipeline. Headquartered in San Diego, California, the company leverages its U.S. discovery experience alongside preclinical resources in China to support global development and pursue partnerships with industry and academia.

Innovo Therapeutics holds worldwide exclusive rights to Rosmantuzumab, an anti-RSPO3 monoclonal antibody that is in Phase 2. It is actively engaged in discussions to advance its pipeline through pharma partnerships. The organization comprises a small team and emphasizes validated biology and an efficient discovery process to drive execution and growth through collaborations.

Sign up for free to view info

Company overview Employee directory